| scholarly article | Q13442814 |
| P50 | author | Silvestre Vicent | Q38545098 |
| Vicki Huff | Q59617066 | ||
| William C Hahn | Q88192808 | ||
| David E Root | Q89000283 | ||
| P2093 | author name string | Sakina Saif | |
| E Alejandro Sweet-Cordero | |||
| Chenwei Lin | |||
| Xiaoping Yang | |||
| Aravind Subramanian | |||
| Ron Chen | |||
| Leanne C Sayles | |||
| Anna K Gillespie | |||
| Gregory Hinkle | |||
| Randal G Walker | |||
| P2860 | cites work | Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling | Q22003910 |
| Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence | Q24309539 | ||
| Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a | Q24324559 | ||
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| A biomarker that identifies senescent human cells in culture and in aging skin in vivo | Q24562644 | ||
| A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene | Q24647664 | ||
| The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi | Q24655084 | ||
| An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets | Q24792966 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity | Q28294122 | ||
| Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation | Q28509874 | ||
| PML is a direct p53 target that modulates p53 effector functions | Q28586691 | ||
| ras oncogenes in human cancer: a review | Q29547769 | ||
| Oncogenic pathway signatures in human cancers as a guide to targeted therapies | Q29615526 | ||
| Diagnosis of multiple cancer types by shrunken centroids of gene expression | Q29615528 | ||
| Multiclass cancer diagnosis using tumor gene expression signatures | Q29615780 | ||
| A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference | Q29615920 | ||
| Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses | Q29616071 | ||
| Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction | Q29616653 | ||
| Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 | Q29617043 | ||
| c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism | Q29617213 | ||
| Radiation-induced cell cycle arrest compromised by p21 deficiency | Q29620237 | ||
| A loss-of-function RNA interference screen for molecular targets in cancer | Q33237976 | ||
| Cancer proliferation gene discovery through functional genomics. | Q33317743 | ||
| The transcriptional network for mesenchymal transformation of brain tumours. | Q33572162 | ||
| Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer | Q33788519 | ||
| KLF4, p21 and context-dependent opposing forces in cancer | Q34478868 | ||
| Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers | Q34688930 | ||
| Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study | Q34798314 | ||
| The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the developing testis | Q35033140 | ||
| PML is induced by oncogenic ras and promotes premature senescence | Q35201220 | ||
| Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization | Q35207910 | ||
| Senescence of human fibroblasts induced by oncogenic Raf | Q35210205 | ||
| Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis | Q35677359 | ||
| Detection of chimeric transcripts in desmoplastic small round cell tumor and related developmental tumors by reverse transcriptase polymerase chain reaction. A specific diagnostic assay | Q35796489 | ||
| Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 | Q36174385 | ||
| Wilms' tumour: connecting tumorigenesis and organ development in the kidney | Q36234726 | ||
| Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria | Q36453541 | ||
| Oncogene-induced cell senescence--halting on the road to cancer | Q36587198 | ||
| Production of immortalized distal respiratory epithelial cell lines from surfactant protein C/simian virus 40 large tumor antigen transgenic mice | Q36686163 | ||
| A tumor suppressor and oncogene: the WT1 story. | Q36760031 | ||
| Senescence in tumours: evidence from mice and humans | Q36903843 | ||
| Effects of RAS on the genesis of embryonal rhabdomyosarcoma. | Q38301662 | ||
| A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer | Q38351528 | ||
| The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development | Q38352220 | ||
| Cdk2 suppresses cellular senescence induced by the c-myc oncogene. | Q39763259 | ||
| Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells | Q39843809 | ||
| WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression | Q39958704 | ||
| Profiling essential genes in human mammary cells by multiplex RNAi screening | Q40018285 | ||
| A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells | Q40572608 | ||
| Somatic activation of the K-ras oncogene causes early onset lung cancer in mice | Q40809826 | ||
| Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. | Q42945812 | ||
| A negative feedback signaling network underlies oncogene-induced senescence | Q43116108 | ||
| An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis | Q47608135 | ||
| Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. | Q47745236 | ||
| Immunohistochemical detection of WT1 protein in a variety of cancer cells | Q48612464 | ||
| Requirement for Rac1 in a K-ras induced lung cancer in the mouse | Q53329326 | ||
| Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor | Q72428441 | ||
| Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers | Q74456077 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nephroblastoma | Q756289 |
| P304 | page(s) | 3940-3952 | |
| P577 | publication date | 2010-10-25 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models | |
| P478 | volume | 120 |
| Q36360310 | 'Big data' approaches for novel anti-cancer drug discovery |
| Q37724940 | A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer |
| Q43496062 | A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer |
| Q37284373 | A novel immunogenic CS1‐specific peptide inducing antigen‐specific cytotoxic T lymphocytes targeting multiple myeloma |
| Q60327011 | A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype |
| Q34137070 | A primer on using pooled shRNA libraries for functional genomic screens |
| Q82872622 | A regulator of senescence |
| Q38329647 | Addressing the right targets in oncology: challenges and alternative approaches |
| Q40324354 | An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. |
| Q90170499 | Antagonistic activities of CDC14B and CDK1 on USP9X regulate WT1-dependent mitotic transcription and survival |
| Q42085487 | Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer |
| Q28253465 | DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia |
| Q92036703 | Deubiquitinase inhibitor degrasyn suppresses metastasis by targeting USP5-WT1-E-cadherin signalling pathway in pancreatic ductal adenocarcinoma |
| Q37632641 | Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. |
| Q34380368 | Development of synthetic lethality anticancer therapeutics |
| Q28079559 | Drugging the addict: non-oncogene addiction as a target for cancer therapy |
| Q35163434 | Drugging the undruggable RAS: Mission possible? |
| Q26765402 | Epigenetic regulators and their impact on therapy in acute myeloid leukemia |
| Q21563374 | Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population |
| Q30531111 | Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells |
| Q90357653 | From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers |
| Q90670701 | Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis |
| Q88688533 | Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets |
| Q34247032 | High-order SNP combinations associated with complex diseases: efficient discovery, statistical power and functional interactions |
| Q36750622 | Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. |
| Q40429284 | K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth |
| Q38057476 | KRAS Mutations in Lung Cancer |
| Q38390027 | KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach |
| Q64120316 | KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition |
| Q38622790 | Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets |
| Q24610335 | Molecular biology of lung cancer: clinical implications |
| Q38088500 | Mouse models for lung cancer |
| Q37874368 | Never-ageing cellular senescence |
| Q34617481 | Oxygen-Dependent Gene Expression in Development and Cancer: Lessons Learned from the Wilms' Tumor Gene, WT1 |
| Q94545721 | Phenotypic screening using large-scale genomic libraries to identify drug targets for the treatment of cancer |
| Q37491175 | Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis. |
| Q35683647 | RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally |
| Q28260541 | RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? |
| Q36398735 | RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies |
| Q37974687 | RAS signalling in the colorectum in health and disease. |
| Q35117739 | RAS transformation requires CUX1-dependent repair of oxidative DNA damage. |
| Q39004151 | RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression |
| Q36331953 | Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma |
| Q37290498 | Senescence Process in Primary Wilms' Tumor Cell Culture Induced by p53 Independent p21 Expression |
| Q38238743 | Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer |
| Q48611990 | Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers |
| Q64104202 | Synthetic Lethality in Lung Cancer-From the Perspective of Cancer Genomics |
| Q28072904 | Synthetic lethality in lung cancer and translation to clinical therapies |
| Q26851163 | Targeting NADPH oxidases for the treatment of cancer and inflammation |
| Q35894216 | Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33 |
| Q38799845 | Targeting the KRAS Pathway in Non-Small Cell Lung Cancer |
| Q47639653 | The CUG-translated WT1, not AUG-WT1, is an oncogene |
| Q42292345 | The DNA repair function of CUX1 contributes to radioresistance |
| Q92234328 | The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas |
| Q90637881 | The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism |
| Q39271171 | The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence |
| Q47388677 | The transcriptional coregulator NAB2 is a target gene for the Wilms' tumor gene 1 protein (WT1) in leukemic cells |
| Q39262217 | Therapeutic Strategies for Targeting Ras Proteins |
| Q37890867 | Towards systematic functional characterization of cancer genomes |
| Q37970854 | Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics |
| Q37848203 | Tumour-associated antigens: considerations for their use in tumour immunotherapy. |
| Q45837056 | Two Is Better Than One: Combining IGF1R and MEK Blockade as a Promising Novel Treatment Strategy Against KRAS-Mutant Lung Cancer |
| Q36268425 | USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. |
| Q33651791 | Use of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions |
| Q38826671 | WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma |
| Q37940867 | WT1 in disease: shifting the epithelial-mesenchymal balance. |
| Q34221445 | WT1 interacts with MAD2 and regulates mitotic checkpoint function |
| Q34924201 | WT1 promotes cell proliferation in non-small cell lung cancer cell lines through up-regulating cyclin D1 and p-pRb in vitro and in vivo |
| Q34245506 | WT1: a weak spot in KRAS-induced transformation |
| Q26744111 | Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia |
| Q55318193 | Wilms' Tumor Protein 1 and Enzymatic Oxidation of 5-Methylcytosine in Brain Tumors: Potential Perspectives. |
| Q35157134 | Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. |
| Q56981752 | Wilms' tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease |
| Q47948619 | Wilms' tumour 1 (WT1) in development, homeostasis and disease. |
| Q35095712 | Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene |
Search more.